title: Tumor-associated hyaluronan limits efficacy of monoclonal antibody therapy.
abstract: Despite tremendous progress in cancer immunotherapy for solid tumors, clinical success of monoclonal antibody (mAb) therapy is often limited by poorly understood mechanisms associated with the tumor microenvironment (TME). Accumulation of hyaluronan (HA), a major component of the TME, occurs in many solid tumor types, and is associated with poor prognosis and treatment resistance in multiple malignancies. In this study, we describe that a physical barrier associated with high levels of HA (HA(high)) in the TME restricts antibody and immune cell access to tumors, suggesting a novel mechanism of in vivo resistance to mAb therapy. We determined that approximately 60% of HER2(3+) primary breast tumors and approximately 40% of EGFR(+) head and neck squamous cell carcinomas are HA(high), and hypothesized that HA(high) tumors may be refractory to mAb therapy. We found that the pericellular matrix produced by HA(high) tumor cells inhibited both natural killer (NK) immune cell access to tumor cells and antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro. Depletion of HA by PEGPH20, a pegylated recombinant human PH20 hyaluronidase, resulted in increased NK cell access to HA(high) tumor cells, and greatly enhanced trastuzumab- or cetuximab-dependent ADCC in vitro. Furthermore, PEGPH20 treatment enhanced trastuzumab and NK cell access to HA(high) tumors, resulting in enhanced trastuzumab- and NK cell-mediated tumor growth inhibition in vivo. These results suggest that HA(high) matrix in vivo may form a barrier inhibiting access of both mAb and NK cells, and that PEGPH20 treatment in combination with anticancer mAbs may be an effective adjunctive therapy for HA(high) tumors.
authors.affiliation: Halozyme Therapeutics, Inc., San Diego, California.
authors.forename: Netai C
authors.initials: NC
authors.lastname: Singha
authors.affiliation: Halozyme Therapeutics, Inc., San Diego, California.
authors.forename: Tara
authors.initials: T
authors.lastname: Nekoroski
authors.affiliation: Halozyme Therapeutics, Inc., San Diego, California.
authors.forename: Chunmei
authors.initials: C
authors.lastname: Zhao
authors.affiliation: Halozyme Therapeutics, Inc., San Diego, California.
authors.forename: Rebecca
authors.initials: R
authors.lastname: Symons
authors.affiliation: Halozyme Therapeutics, Inc., San Diego, California.
authors.forename: Ping
authors.initials: P
authors.lastname: Jiang
authors.affiliation: Intrexon Corporation, San Diego, California.
authors.forename: Gregory I
authors.initials: GI
authors.lastname: Frost
authors.affiliation: Halozyme Therapeutics, Inc., San Diego, California.
authors.forename: Zhongdong
authors.initials: Z
authors.lastname: Huang
authors.affiliation: Halozyme Therapeutics, Inc., San Diego, California. mshepard@halozyme.com.
authors.forename: H Michael
authors.initials: HM
authors.lastname: Shepard
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects; D002450:Cell Communication / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D066246:ErbB Receptors / Q000378:metabolism; D005109:Extracellular Matrix / Q000378:metabolism; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000378:metabolism* / Q000494:pharmacology; D007694:Killer Cells, Natural / Q000378:metabolism; D008819:Mice, Nude; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D000068878:Trastuzumab; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D066246:ErbB Receptors; D006820:Hyaluronic Acid; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human